InnoTherapy Correlations
| 246960 Stock | KRW 8,480 40.00 0.47% |
The current 90-days correlation between InnoTherapy and High Tech Pharm is 0.02 (i.e., Significant diversification). The correlation of InnoTherapy is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
InnoTherapy |
The ability to find closely correlated positions to InnoTherapy could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace InnoTherapy when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back InnoTherapy - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling InnoTherapy to buy it.
Moving together with InnoTherapy Stock
| 0.75 | 102940 | Kolon Life Science | PairCorr |
| 0.68 | 074430 | Aminologics CoLtd | PairCorr |
| 0.81 | 023910 | Daihan Pharmaceutical | PairCorr |
| 0.84 | 047920 | HLB Pharmaceutical | PairCorr |
| 0.79 | 330350 | Withuspharmaceutical | PairCorr |
| 0.7 | 009300 | Sam A Pharm | PairCorr |
| 0.87 | 254120 | Xavis | PairCorr |
| 0.85 | 353190 | Hurum | PairCorr |
| 0.72 | 030350 | Dragonfly GF Split | PairCorr |
Moving against InnoTherapy Stock
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Risk-Adjusted Indicators
There is a big difference between InnoTherapy Stock performing well and InnoTherapy Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze InnoTherapy's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 102940 | 1.40 | (0.34) | 0.00 | 3.49 | 0.00 | 3.11 | 8.97 | |||
| 074430 | 1.44 | (0.32) | 0.00 | 0.94 | 0.00 | 2.76 | 13.89 | |||
| 330350 | 1.54 | (0.31) | 0.00 | (40.77) | 0.00 | 3.33 | 9.83 | |||
| 106190 | 1.92 | (0.10) | 0.00 | 0.39 | 0.00 | 4.35 | 11.21 |
Be your own money manager
Our tools can tell you how much better you can do entering a position in InnoTherapy without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Insider Screener Now
Insider ScreenerFind insiders across different sectors to evaluate their impact on performance |
| All Next | Launch Module |
InnoTherapy Corporate Executives
Elected by the shareholders, the InnoTherapy's board of directors comprises two types of representatives: InnoTherapy inside directors who are chosen from within the company, and outside directors, selected externally and held independent of InnoTherapy. The board's role is to monitor InnoTherapy's management team and ensure that shareholders' interests are well served. InnoTherapy's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, InnoTherapy's outside directors are responsible for providing unbiased perspectives on the board's policies.
| HaeShin Lee | Founder CTO | Profile | |
| In Moon | COO CFO | Profile |